Shire wins EMA blessing for Replagal plant

Shire has won European approval for its new manufacturing site in the U.S., allowing the U.K. company to ramp up production of its products, including Replagal for Fabry disease. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.